🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,071 results for “tablet” Clear

  1. Abemaciclib, TEMOZOLOMIDE , Verzenios 50 mg film-coated tablets, IRINOTECAN

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  2. Active drug: pimavanserin 17mg (2 strength tablets)

    Acadia Pharmaceuticals B.V.

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  3. Alunbrig 30 mg film-coated tablets, CRIZOTINIB, LORLATINIB, Zykadia 150 mg hard capsules, ALECTINIB

    The George Institute

    locally advanced (stage III) and not suitable for curative treatment, or metastatic (stage IV) ALK+ NSCLC, ALK+ NSCLC

    phase 2 small molecule active

    1 trial

  4. Amifampridine Phosphate 10 MG Oral Tablet

    CATALYST PHARMACEUTICALS, INC.

    Spinal Muscular Atrophy Type 3

    phase 2 small molecule terminated

    1 trial

  5. Amimox 500 mg filmdragerade tabletter, Kåvepenin 800 mg filmdragerade tabletter

    The George Institute

    Need of Oral bone augmentation

    phase 2 small molecule active

    1 trial

  6. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  7. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  8. Apatinib mesylate tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  9. Apatinib mesylate tablets

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  10. Atorvastatin Oral Tablet

    Chongqing Precision Biotech Co., Ltd

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial

  11. Atorvastatina Teva Italia 80 mg compresse rivestite con film, Film-coated tablets, white, shaped elliptical, and coated with smooth film. The dimensions of each tablet are approximately 18.8 mm x 10.3 mm (identical to those containing atorvastatin).

    Cardiol Therapeutics

    Arrhythmogenic Cardiomyopathy (ACM)

    phase 2 small molecule active

    1 trial

  12. Aumolertinib Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lung Cancer Stage IV

    phase 2 small molecule active

    1 trial

  13. Avapritinib, Avapritinib, Avapritinib Placebo Tablets

    Blueprint Medicines (Netherlands) B.V.

    Indolent Systemic Mastocytosis (ISM)

    phase 2 small molecule active

    1 trial

  14. Avastin 25 mg/ml concentrate for solution for infusion., Lynparza 150 mg film-coated tablets, Cotellic 20 mg film-coated tablets, Ipatasertib, Cotellic, Cotellic, INAVOLISIB, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, Verzenios 50 mg film-coated tablets, Cotellic, Lynparza 100 mg film-coated tablets, Kadcyla 160 mg powder for concentrate for solution for infusion., LETRO-cell® 2,5 mg Filmtabletten, INAVOLISIB, Verzenios 100 mg film-coated tablets, INAVOLISIB, Lynparza 150 mg film-coated tablets

    Hoffmann-La Roche

    Persistent or Recurrent Rare Epithelial Ovarian Tumors

    phase 2 small molecule active

    1 trial

  15. Avastin 25 mg/ml concentrate for solution for infusion., Tecentriq, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion, Camonsertib, Trajenta 5 mg film-coated tablets

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  16. Axatilimab (INCA034176), PREDNISONE, METHYLPREDNISOLONE, Jakavi 5 mg tablets

    Incyte

    chronic graft-versus-host disease

    phase 2 small molecule active

    1 trial

  17. Azacitidine 150mg tablet, Azacitidine 200mg tablet: film- coated tablet, azacitidine, PEMBROLIZUMAB, azacitidine

    Celgene Europe Limited

    Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  18. BET-Inhibitor, Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, FEDRATINIB

    Bristol-Myers Squibb Australia Pty Ltd

    DIPSS-Intermediate or High Risk Myelofibrosis

    phase 2 small molecule active

    1 trial

  19. BEVACIZUMAB, DC-VACCINE_IRSTIRCCS, Lonsurf 20 mg/8.19 mg film-coated tablets, VEGZELMA 25 mg/mL concentrate for solution for infusion, VEGZELMA 25 mg/mL concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BEVACIZUMAB

    Istituto Gentili S.r.l.

    Metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  20. BI 1819479, Placebo, Film-coated tablet, matching in size, weight, colour and shape to BI 1819479 (both unit strengths), BI 1819479

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  21. BI 1839100, Placebo matching in size, weight, colour and shape to tablets of BI 1839100

    Boehringer Ingelheim

    Progressive pulmonary fibrosis (PPF), Idiopathic pulmonary fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  22. BI 690517, Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat

    Boehringer Ingelheim

    chronic kidney disease

    phase 2 small molecule active

    1 trial

  23. BRENSOCATIB, MOMETASONE , BRENSOCATIB, The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP.

    Insmed Limited

    Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

    phase 2 small molecule active

    1 trial

  24. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources